PMID- 25818246
OWN - NLM
STAT- MEDLINE
DCOM- 20160531
LR  - 20150908
IS  - 1878-4216 (Electronic)
IS  - 0278-5846 (Linking)
VI  - 64
DP  - 2016 Jan 4
TI  - MDMA-assisted therapy: A new treatment model for social anxiety in autistic 
      adults.
PG  - 237-49
LID - S0278-5846(15)00060-3 [pii]
LID - 10.1016/j.pnpbp.2015.03.011 [doi]
AB  - The first study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for 
      the treatment of social anxiety in autistic adults commenced in the spring of 
      2014. The search for psychotherapeutic options for autistic individuals is 
      imperative considering the lack of effective conventional treatments for mental 
      health diagnoses that are common in this population. Serious Adverse Events 
      (SAEs) involving the administration of MDMA in clinical trials have been rare and 
      non-life threatening. To date, MDMA has been administered to over 1133 
      individuals for research purposes without the occurrence of unexpected 
      drug-related SAEs that require expedited reporting per FDA regulations. Now that 
      safety parameters for limited use of MDMA in clinical settings have been 
      established, a case can be made to further develop MDMA-assisted therapeutic 
      interventions that could support autistic adults in increasing social 
      adaptability among the typically developing population. As in the case with 
      classic hallucinogens and other psychedelic drugs, MDMA catalyzes shifts toward 
      openness and introspection that do not require ongoing administration to achieve 
      lasting benefits. This infrequent dosing mitigates adverse event frequency and 
      improves the risk/benefit ratio of MDMA, which may provide a significant 
      advantage over medications that require daily dosing. Consequently, clinicians 
      could employ new treatment models for social anxiety or similar types of distress 
      administering MDMA on one to several occasions within the context of a supportive 
      and integrative psychotherapy protocol.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Danforth, Alicia L
AU  - Danforth AL
AD  - Los Angeles Biomedical Research Institute, Torrance, CA, United States. 
      Electronic address: adanforth@labiomed.org.
FAU - Struble, Christopher M
AU  - Struble CM
AD  - Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, CA, United 
      States. Electronic address: cstruble.md@gmail.com.
FAU - Yazar-Klosinski, Berra
AU  - Yazar-Klosinski B
AD  - Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, United 
      States. Electronic address: Berra@MAPS.org.
FAU - Grob, Charles S
AU  - Grob CS
AD  - Department of Psychiatry, Harbor-UCLA Medical Center, Los Angeles Biomedical 
      Research Institute, Torrance, CA, United States. Electronic address: 
      cgrob@labiomed.org.
LA  - eng
SI  - ClinicalTrials.gov/NCT02008396
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150325
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Psychotropic Drugs)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Anxiety Disorders/complications/*drug therapy/physiopathology
MH  - Autistic Disorder/complications/*drug therapy/physiopathology
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Humans
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage/adverse effects
MH  - Patient Selection
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Psychotropic Drugs/*administration & dosage/adverse effects
MH  - Research Design
MH  - Social Perception
OTO - NOTNLM
OT  - Autism
OT  - Ecstasy
OT  - MDMA
OT  - Psychedelics
OT  - Psychotherapy
OT  - Social anxiety
EDAT- 2015/03/31 06:00
MHDA- 2016/06/01 06:00
CRDT- 2015/03/31 06:00
PHST- 2015/01/01 00:00 [received]
PHST- 2015/03/16 00:00 [revised]
PHST- 2015/03/17 00:00 [accepted]
PHST- 2015/03/31 06:00 [entrez]
PHST- 2015/03/31 06:00 [pubmed]
PHST- 2016/06/01 06:00 [medline]
AID - S0278-5846(15)00060-3 [pii]
AID - 10.1016/j.pnpbp.2015.03.011 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:237-49. doi: 
      10.1016/j.pnpbp.2015.03.011. Epub 2015 Mar 25.